Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Pemetrexed and Sorafenib for Treatment of Recurrent or Metastatic Triple Negative Breast Cancer

NCT02624700 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT02624700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02624700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Pemetrexed and Sorafenib for Treatment of Recurrent or Metastatic Triple Negative Breast Cancer
Lead sponsor
Virginia Commonwealth University
Phase
Phase 2
Overall status
Terminated
Start date
January 28, 2016
Completion date
July 10, 2019
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastatic breast cancer, recurrent breast cancer